Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Sees Generics Opportunity In Japan For Innovator Companies

This article was originally published in PharmAsia News

Executive Summary

A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito
Advertisement

Related Content

Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Eisai Plans R&D Revamp To Turn The Development Tide
Eisai Plans R&D Revamp To Turn The Development Tide
Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
Will Priority Prescription Cards Help Japan Promote Generics?
Will Priority Prescription Cards Help Japan Promote Generics?
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Advertisement
UsernamePublicRestriction

Register

SC070847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel